Affinivax

Cambridge, United States Founded: 2013 • Age: 13 yrs Acquired By GSK
Technology-based conjugate vaccines against infectious diseases are developed.
Request Access

About Affinivax

Affinivax is a company based in Cambridge (United States) founded in 2013 was acquired by GSK in May 2022.. Affinivax has raised $359.49 million across 5 funding rounds from investors including BlackRock, Bain Capital and T. Rowe Price. The company has 132 employees as of December 31, 2022. Affinivax operates in a competitive market with competitors including Brii Biosciences, Insmed, Neon Therapeutics, Eligo Bioscience and Lodo Therapeutics, among others.

  • Headquarter Cambridge, United States
  • Employees 132 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Affinivax Inc
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $359.49 M (USD)

    in 5 rounds

  • Latest Funding Round
    $226 M (USD), Series C

    Jan 07, 2021

  • Investors
    BlackRock

    & 15 more

  • Employee Count
    132

    as on Dec 31, 2022

  • Acquired by
    GSK

    (May 31, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Affinivax
Headcount 50-200
Employee Profiles 17
Board Members and Advisors 7
Employee Profiles
People
Frank Malinoski
SVP, Clinical Development & Regulatory Affairs
People
Ryan Burke
Director Supply Chain Planning
People
Wajih Yazbek
Reseach Associate II
People
Jun Zhang
Director, Drug Product Formulation And Process Development

Unlock access to complete

Funding Insights of Affinivax

Affinivax has successfully raised a total of $359.49M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $226 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series C — $226.0M
  • First Round

    (30 Oct 2014)

  • Investors Count 15
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2021 Amount Series C - Affinivax Valuation Rock Springs Capital , Foresite Capital
Apr, 2020 Amount Series B - Affinivax Valuation Viking Global Investors
Dec, 2017 Amount Series A - Affinivax Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Affinivax

Affinivax has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Bain Capital and T. Rowe Price. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage and late-stage biotech and finance companies are funded.
Founded Year Domain Location
Multi-stage investment firm invests in healthcare and life sciences companies
Founded Year Domain Location
Health-tech companies are targeted for venture capital investments.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Affinivax

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Affinivax

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Affinivax Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Affinivax

Affinivax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, Insmed, Neon Therapeutics, Eligo Bioscience and Lodo Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of biologics to treat hepatitis B infection
domain founded_year HQ Location
Developer of small molecule inhibitors for rare lung diseases
domain founded_year HQ Location
Tumor-specific neoantigens are identified for personalized cancer vaccine development.
domain founded_year HQ Location
In vivo gene editing technology is developed for microbiome modulation.
domain founded_year HQ Location
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Affinivax

Frequently Asked Questions about Affinivax

When was Affinivax founded?

Affinivax was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Affinivax located?

Affinivax is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Is Affinivax a funded company?

Affinivax is a funded company, having raised a total of $359.49M across 5 funding rounds to date. The company's 1st funding round was a Series A of $6.99M, raised on Oct 30, 2014.

How many employees does Affinivax have?

As of Dec 31, 2022, the latest employee count at Affinivax is 132.

What does Affinivax do?

Affinivax was established in 2013 in Cambridge, United States, within the biotechnology sector. Conjugate vaccines targeting infectious diseases are developed using the Multiple Antigen-Presenting System (MAPS) platform. Protective polysaccharides and proteins are conjugated into a single formulation through this technology. A broad immune response is elicited against pathogenic microorganisms. Operations center on advancing vaccine programs for various infectious threats.

Who are the top competitors of Affinivax?

Affinivax's top competitors include Brii Biosciences, Insmed and Osivax.

Who are Affinivax's investors?

Affinivax has 16 investors. Key investors include BlackRock, Bain Capital, T. Rowe Price, Citadel, and Gates Foundation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available